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http://www.biomedcentral.com/1471-2407/12/437RESEARCH ARTICLE Open AccessCHD1L Protein is overexpressed in human
ovarian carcinomas and is a novel predictive
biomarker for patients survival
Wei-Peng He1, Juan Zhou1, Mu-Yan Cai2, Xiang-Shen Xiao2, Yi-Ji Liao2, Hsiang-Fu Kung3, Xin-Yuan Guan2,
Dan Xie2 and Guo-Fen Yang1*Abstract
Background: Our recent studies suggested that the chromodomain helicase DNA binding protein 1-like (CHD1L)
gene plays an oncogenic role in human hepatocellular carcinoma. However, the status of CHD1L protein expression
in ovarian cancer and its clinical/prognostic significance are obscure.
Methods: In this study, immunohistochemistry (IHC) for CHD1L was performed on a tissue microarray (TMA)
containing 102 primary ovarian carcinomas and 44 metastatic lesions (omental metastasis). Receiver-operator curve
(ROC) analysis was used to evaluate patients’ survival status.
Results: There is an augmented tendency of CHD1L expression in ovarian carcinoma metastasis than in primary
lesions (P<0.05). A significant association was found between positive expression of CHD1L and tumors histological
type (P <0.05). By univariate survival analysis of the ovarian carcinoma cohorts, positive expression of CHD1L was
significantly correlated with shortened patient survival (mean 66.7 months versus 97.4 months, P<0.05). Moreover,
CHD1L expression was evaluated to be a significant and independent prognostic factor in multivariate analysis
(P<0.05).
Conclusions: These findings provide evidence that positive expression of CHD1L protein is significantly correlated
with the metastasis proceeding of ovarian carcinoma, and CHD1L protein expression, as examined by IHC, may act
as a novel prognostic biomarker for patients with ovarian carcinoma.Background
Ovarian cancer, the leading cause of death from a
gynecological malignancy, has increasing incidence re-
cently in China and Singapore [1]. The onset age for
ovarian cancer is about 45 years old [2]. On account of
the absence of early diagnosis methods and the absence
of characteristic symptoms, the majority of ovarian can-
cer patients (70%) were diagnosed at FIGO III/IV, and
had a unfavorable prognosis with a 5-year survival rate
of <20% [3]. Recently, ovarian cancer was considered as
a more complicated genetic change and multiple-step
patho-physiological change [4]. Clinically, most ovarian
cancers are ovarian carcinoma. It is prevalent to* Correspondence: pgf_yang@126.com
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reproduction in any medium, provided the ordiscovery a tumor marker for the diagnosis and progno-
sis of ovarian carcinoma, as well as developing targeted
therapy, predicting the survival, and predicting relapse.
Recently, we reported that the chromodomain helicase
DNA binding protein 1-like (CHD1L) gene is a putative
oncogene mapped to chromosome 1q21 and it is asso-
ciated with hepatocellular carcinoma (HCC) tumorigen-
esis [5]. CHD1L belongs to SNF-2family, which contains
a domain (approximately 400 amino acids) with highly
conserved helicase motifs [5]. The full-length mRNA
(2.98kb) of CHD1L encodes an 897aa protein. Most
SNF2-like proteins participate in various nuclear activ-
ities, such as transcriptional activation or repression,
DNA repair and recombination [6,7]. In HCC patients,
over 50% cases have overexpression of CHD1L, which is
associated with the carcinoma progression and metasta-
sis and predict the poor prognosis of the survival statusThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association of CHD1L protein expression with
clinic-pathological parameter
CHD1L protein expression
Variable Allcase negative positive P Valuea
Age at surgery (years) 0.168
≤ 51 b 54 23(52.6%) 31(57.4%)
> 51 48 27(56.2%) 21(43.8%)
Histological type
Serous 72 35(48.6%) 37(51.4%) 0.029
Mucinous 11 9(81.8%) 2(18.2%)
Othersc 19 6(32.6%) 13(68.4%)
Histologicalgrade(Silveberg) 0.745
G1 16 9(56.2%) 7(43.8%)
G2 61 30(48.2%) 31(50.8%)
G3 25 11(44.0%) 14(56.0%)
FIGO stage 0.354
I 19 8(42.1%) 11(57.9%)
II 10 7(70.0%) 3(30.0%)
III 58 26(44.8%) 32(55.2%)
IV 15 9(60.0%) 6(40.0%)
Residual tumor 0.469
None 32 15(46.9%) 17(53.1%)
<=2cm 35 15(42.9%) 20(57.1%)
>2cm 35 20(47.1%) 15(42.9%)
aChi-square test.
b Mean age.
cEndometrioid, Clear cell and Undifferentiated types.
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protein in ovarian carcinoma tissue and its prognostic
significance has not been elucidated.
In this study, therefore, we examined the expression
status of CHD1L protein by IHC in a cohort of ovarian
carcinoma tissues (including 102 primary lesions and 44
corresponding metastatic lesions). The clinical/prognostic
significance of CHD1L expression in our ovarian carcin-
oma cohort was assessed.
Methods
Patients and tissue specimens
In this study, paraffin-embedded tissue samples from
102 patients with ovarian carcinoma and corresponding
44 cases metastasis were obtained from the archives of
Department of Pathology, the First Affiliated Hospital,
Sun Yat-Sen University, Guangzhou, China, between
1996 and 2008. The patients selected were based on
availability of resection tissue, follow-up data, and had
not accepted preoperative radiation or chemotherapy.
Patients died from unknown causes or emergency were
excluded from this study. The age of the 102 patients
with ovarian carcinoma ranged from 18 to 86 years
(mean, 51.0 years) and their clinico-pathological charac-
teristics are described in Table 1. Prior patient’s
informed consent and the Institute Research Medical
Ethics Committee of Sun Yat-Sen University granted ap-
proval for this study.
Construction of tissue microarrays (TMA)
The tissue microarray was constructed as previously
described [9-11]. The formalin-fixed, paraffin-embedded
tissue blocks and the corresponding histological HE-
stained slides were overlaid for tissue TMA sampling.
Our senior pathologist reviewed the slides and marked
the representative areas of tumor tissues. We used a
tissue arraying instrument (Beecher Instruments, Silver
Spring, MD, USA) to punch triplicate 0.6-mm-diam-
eter cylinders of tissue from selected cancer areas of
individual donor tissue block and re-embed into a re-
cipient paraffin block at a predefined position. The
TMA blocks included 102 ovarian carcinomas and 44
corresponding metastasis lesions. Subsequently, mul-
tiple sections (5-um thick) were cut from the TMA
tissue array.
Immunohistochemistry (IHC)
The immunohistochemical study of CHD1L was per-
formed using a standard streptavidin-peroxidase method
demonstrated previously [12]. The endogenous peroxid-
ase activity was blocked with 3% H2O2 for 10 minutes.
For the antigen retrieval, slides were immersed in 10
mM citrate buffer (pH 6.0) and boiled for 15 minutes in
a microwave oven. Non-specific binding was blocked by5% normal goat serum for 10 minutes. The slides were
incubated with a 1:100 dilution of monoclonal antibody
against CHD1L (Abcam) at 4°C overnight in a moist
chamber. The slides were sequentially incubated with
biotinylated goat anti-mouse IgG (1:100 dilution; Santa
Cruz Biotechnology) and then streptavidin-peroxidase
conjugate, each for 30 minutes at room temperature.
Isotope-matched human IgG was used in each case as a
negative control. Finally, the 3, 5-diaminobenzidine
(DAB) Substrate Kit (Dako) was used for color develop-
ment followed by Mayer hematoxylin counterstaining.
For the evaluation of CHD1L staining, a semi-
quantitative scoring criterion was used, in which both
staining intensity and positive cells percentage were con-
tained [12,13]. A staining index (with values from 0 to
12) was obtained as the intensity of CHDIL staining
(0=negative, 1=weakly positive, 2=positive, 3=strongly
positive) times the proportion of immunopositive tumor
cells (0%=0;<10%=1;10%≤ to<50%=2;50%≤to <75%
=3;≥75%=4 ). All histological evaluations were carried
out in a double-blind manner by two expert pathologists
(M-YC and DX).
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Statistical analysis was executed with the SPSS statistical
software package (SPSS Standard version 13.0, SPSS
Inc.). We assess the association of CHD1L protein ex-
pression with clinico-pathological features by the Chi-
square test or Fishers’ exact test. Wilcoxon Signed Ranks
Test is used to compare the CHD1L protein expression
between the primary ovarian carcinomas and metastasis.
Multivariate survival analysis was performed on all fac-
tors which have been proved to be significant on uni-
variate analysis by the Cox regression model. For
univariate survival analysis, Kaplan–Meier analysis is
used. We utilized Log rank test to compare different sur-
vival curves. ROC analysis is used to compare the
clinico-pathological features for estimation of the sur-
vival prediction. P value of <0.05 was considered statisti-
cally significant.Results
CHD1L protein expression in primary ovarian carcinomas
and corresponding metastatic lesions
For CHD1L protein IHC staining in ovarian carcinoma
tissues, positive staining was seen primarily in the nuclei
within tumor cells, though occasionally yellowish brown
granules could be also observed in the cytoplasm
(Figure 1). The median score of CHD1L protein expres-
sion in the primary ovarian lesions is 4, while the score in
the metastasis is 7. The difference between the levels ofFigure 1 The protein expression patterns of CHD1L in primary ovaria
CHD1L protein was observed in a primary ovarian lesions (case 75), in whic
CHD1L in nuclei (upper panel, ×40). (B) A primary ovarian lesion case (case
than 80% of tumor cells showed high immunoreactivity of CHD1L protein
was demonstrated in a metastatic ovarian lesion case (case 20, upper panel
the area of the box in A, B and C respectively.CHD1L expression in the primary lesions and in the meta-
static lesions was statistically significant (P <0.05, Table 2).
Association of CHD1L protein expression with clinic-
pathological parameters
In this study, according to the staining index above, pro-
tein expression with a scoring index of ≥ 4 (median
score of CHD1L protein expression in the primary ovar-
ian lesions) is defined as positive expression. The asso-
ciations between CHD1L expression in primary ovarian
carcinomas and several clinico-pathological variables are
assessed and displayed in Table 1. The positive expres-
sion of CHD1L protein expression increasingly pre-
sented from mucinous/serous ovarian carcinoma to
others types of tumor, including undifferentiated ovarian
carcinoma. There was no significant difference between
CHD1L protein expression and other clinicopathological
features, such as patients’ age, histological grade, FIGO
stage and residual tumor (P>0.05, Table 1).
Relationship between clinicpathologic variables, CHD1L
protein expression, and ovarian carcinoma patient
survival: univariate survival analysis
In univariate survival analysis, Kaplan-Meier survival curves
and P-values for these curves were manipulated by log-rank
method. Kapla-Meier analysis demonstrated a significant
impact of well-known clinicopathological prognostic fea-
tures such as histological grade, FIGO stage (P< 0.05,
Table 3) and residual tumor (P< 0.05, Table 3). An lesions and in metastatic leisions. (A) Negative expression of
h less than 10% tumor cells revealed positive immunostaining of
45) demonstrated positive expression of CHD1L protein, in which more
in nuclei (upper panel, ×40). (C) Positive expression of CHD1L protein
, ×40). The lower panels indicated the higher magnification (×200) from
Table 2 The expression of CHD1L protein in ovarian primary lesions and corresponding metastatic lesions
Variable CHD1L protein expression score Z value P value*
ovarian primary lesions 4 −2.419 0.016
corresponding metastatic lesions 7
* Wilcoxon Signed Ranks Test, P<0.05.
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patients with CHD1L-positive compared to patients with
CHD1L-negative tumors. Mean overall survival time was
97.4 months for patients with CHD1L-negative expression
compared to only 66.7 months for patients with CHD1L-
positive expression (P< 0.05, Table 3, Figure 2).Table 3 Clinical pathogical parameters and expression of CHD
by univariate survival analysis (log-rank test)
Variable All cases Mean
Age at surgery
≤ 51a 54
> 51 48
Histological type
Serous 72
Mucinous 11
Othersc 19
Histologicalgrade (Silveberg)
G1 16
G2 61
G3 25
FIGO stage
I 19
II 10
III 58
IV 15
Operation
Satisfactory cytoreductive operation 35
Stage operation 32
Unsatisfactory cytoreductive operation 25
Chemical program
TP 17
Cyclophosphamide + Adriamycin + Carbo 41
Others 44
Residual tumor
None 32
<=2cm 35
>2cm 35
CHD1L protein expression
Negative 50
Positive 52
a Mean age.
b Not reach.
cEndometrioid, Clear cell and Undifferentiated types.Independent prognostic factors of epithelial ovarian
carcinoma: multivariate cox regression analysis
A multivariate statistic analysis based on the Cox pro-
portional hazard model was used to test the independent
prognostic value of each clinicopathological feature
(Table 4). Positive expression of CHD1L protein, as well1L for prognosis of 102 patients with ovarian carcinoma
survival (months) Median survival (months) P value
0.75
74.4 NRb
92.9 NRb
78.4 NRb 0.55
62.7 45
88.4 NRb
0.00
116.3 NRb
87.5 NRb
33.3 22
0.00
57.2 NRb
59.1 NRb
34.1 NRb
21.6 NRb
0.00
92.3 NRb
121.4 NRb
47.6 22
0.17
62.0 NRb
83.5 66
63.6 NRb
0.00
121.2 NRb
92.3 NRb
46.5 22
0.03
97.4 NRb
66.7 37
Figure 2 Survival curve for 102 ovarian carcinoma patients according to CHD1L protein expression status (log-rank test). Overall
survival, probability of survival of all patients with ovarian carcinoma: negative expression, n=50; positive expression, n=52.
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residual tumor) which were significant by univariate ana-
lysis, was included in multivariate analysis. The CHD1L
protein was discovered to be an independent prognostic
factor for poor overall survival (P< 0.01, Table 4).Relationship between clinicpathologic variables, CHD1L
protein expression, and ovarian carcinoma patient
survival: receiver operating characteristic curve (ROC)
analysis
The ROC for each clinicopathological parameter clearly
reveal the point on the curve closest to (0.0, 1.0) which
maximizes both sensitivity and specificity for the out-
come. The ROC analysis for each clinicopathological
variables and CHD1L expression (area under the curve
[AUC] =0.622, P=0.05) is carried out to evaluate the
patient’s survival status (Figure 3).Table 4 Multivariate analysis on overall survival (Cox
regression model)
Variable Relative risk 95% confidence interval P value
CHD1La 1.864 2.600-15.992 0.000
FIGO stageb 1.099 1.395 - 6.456 0.005
residual tumorc 0.926 1.253 - 5.089 0.010
a Positive expressin vs Negative expression.
bStage I vs Stage II vs Stage III vs StageIV.
c0cm vs <=2cm vs >2cm.Discussion
CHD1L, the candidate oncogene, has been isolated from
1q21 amplicon and found frequently amplified in hepato-
cellular carcinoma (HCC). Amplification of 1q21 is the
most frequent genetic alteration in human HCC [14]. It
plays an important role in the development and metastasis
of HCC. Gains of 1q21-q25 have been linked to a more
aggressive phenotype with metastatic potential in renal
clear cell carcinoma and squamous cell carcinomas of
lung [15,16]. In ovarian carcinoma and neuroblastoma,
1q21-q22 amplification indicated a drug-resistant pheno-
type [17,18]. CHD1L is activated by poly (ADP-ribose)
(PAR) polymerase-1 (PARP-1), a DNA nick sensor enzyme
that is activated by DNA breaks, during the posttransla-
tional modification process termed “PARylation” [19].
CHD1L normally loosens tightly packaged chromatin to
allow for repairing of DNA damage. In cancer cells, how-
ever, too much CHD1L can overly relax the chromatin,
making the DNA vulnerable to mistake and thus raising
the risk of cancer. However, to date, the expression dy-
namics of CHD1L in ovarian carcinomas has not been
investigated, and its clinico-pathological and/or prognostic
value in ovarian carcinomas remains unknown.
In the present study, IHC staining for CHD1L was
performed in a large cohort of ovarian carcinoma
patients with complete clinicopathological and follow-up
data. Our results clearly showed that the levels of
CHD1L protein presented ascending in the metastatic
lesions of ovarian carcinoma than that in the primary
Figure 3 ROC curve analysis for different clinicopathological parameters and CHD1L protein expression was performed to evaluate the
survival status. FIGO stage (area under the curve [AUC] =0.755, P<0.001), CHD1L protein expression ([AUC] =0.622, P<0.05), Residual tumor
([AUC] =0.737, P<0.001), Pathological grade ([AUC] =0.681, P<0.001) implied significant statistical associations with the survival.
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pression was evaluated between primary ovarian carcin-
omas in different stages. These results are in line with
our previous findings in HCCs, in which we compared
the expression of CHD1L by IHC between primary
HCCs and their paired metastatic tumors, using a tissue
microarray containing 50 pairs of primary and metastatic
HCCs, and found that overexpression of CHD1L was a
key feature in tumor development and metastasis.
Increased expression of CHD1L was often observed at
the invasive front of HCC tumors and correlated with
venous infiltration, microsatellite tumor nodule forma-
tion [8]. These data, taken together, support the hypoth-
esis that CHD1L might play an important role in the
metastatic nature of several types of human cancer, such
as HCC and ovarian carcinoma, and CHD1L protein
overexpression in ovarian carcinoma may facilitate can-
cer cell metastasis. Further analysis demonstrated that
the protein expression of CHD1L was only found to be
correlated with histotypes, but was not found to be cor-
related with some significant impact of well-known clini-
copathologic prognostic features such as histological
grade, FIGO stage. However, in univariate analysis of the
present study, we observed that the mean survival time
for patients with CHD1L protein negative expression
was 97.4 months compared to 66.7 months for patients
with CHD1L protein positive expression( P<0.05). These
findings was also similar to that in a cohort of HCC
patients of our previous study, in which the median
overall survival times in CHD1L-positive HCC patients
is shorter than in CHD1L-negative patients [12].Furthermore, in our study, we discovered that positive
expression of CHD1L was an independent predictor of
shorter overall survival in ovarian carcinomas as evi-
denced by Kaplan-Meier curves and multivariable Cox
proportional hazards regression analysis. In summary,
we did find that CHD1L expression, as detected by IHC,
was a reliable biomarker for the prognosis of ovarian
carcinoma patients, these data supports that CHD1L
might act as a prognostic biomarker for patients with
ovarian carcinoma independent of clinicopathologic
prognostic parameters. More over, comparison of the
progression-free survival rates of the negative expression
(n=45) and positive expression (n=57) groups, shown in
Figure 4, revealed statistical significant difference in the
progression-free survival rate between the two groups
(P=0.054).Thus, the examination of CHD1L expression
by IHC could be used as an additional tool in identifying
those ovarian carcinoma patients at increased risk of
tumor metastasis and/or having a worse prognosis.
These findings imply that CHD1L may play an import-
ant role in ovarian carcinoma development.
With regards to the gene function and oncogenic role
of CHD1L, it is still not thoroughly characterized and
clarified so far. Our recent in vitro and in vivo functional
studies in mice showed that CHD1L contributed to HCC
cell aggressiveness by increasing cell motility and indu-
cing filopodia formation and epithelial-mesenchymal
transition (EMT) via ARHGEF9-mediated Cdc42 activa-
tion. Silencing ARHGEF9 expression by RNAi lagely
abolished the invasive and metastatic abilities of CHD1L
in mice [8]. Furthermore, our investigation of clinical
Figure 4 Kaplan – Meier progression-free survival curves for the negative expression group(n=45) and the positive expression group
(n=57). The difference in progression-free survival rate between the two groups was significant.
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markedly overexpressed in metastatic HCC tissue com-
pared with healthy tissue [8]. These findings suggested
that CHD1LARHGEF9-Cdc42-EMT might be a novel
pathway involved in HCC progression and/or metastasis.
However, the potential oncogenic role and underling
mechanisms of CHD1L in ovarian carcinoma have not
been investigated. Clearly, further studies are needed to
elucidate the mechanisms by which CHD1L promoting
the development and metastasis of ovarian carcinomas in
detail.
Conclusions
In summary, we have shown here that CHD1L protein ex-
pression was significantly higher in in metastatic lesions
than in the primary lesions and that CHD1L expression
was significantly correlated with survival. Therefore,
CHD1L is not only a biomarker associated with ovarian
cancer, but it also appears to be a prognostic factor asso-
ciated with adverse outcome.
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